1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies

Wedgewood Partners' David Rolfe Comments on Gilead Sciences

November 12, 2012 | About:

Gilead Sciences (NASDAQ:GILD) was among our top performers during the third quarter. We believe that the stock's strong performance over the past three months, as well as the past year is quite warranted, as the company is on the cutting edge in developing a cure for the hepatitis C virus (HCV). The Company’s journey down this path began last November with their $11 billion purchase of Pharmasset, Inc. Pharmasset’s flagship drug candidate (PSI-7977, now GS-7977) is undergoing trials indicated for all-oral treatment of HCV and if ultimately approved by the FDA, Gilead could possess a multi-year, multi-billion dollar revenue opportunity. We believe that the market, more recently, has better recognized this opportunity, so we trimmed our positions during the quarter.

From Wedgewood Partners Third Quarter 2012 Review and Outlook.


Rating: 5.0/5 (2 votes)

Comments

Please leave your comment:


GuruFocus has detected 2 Warning Signs with Gilead Sciences Inc $GILD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

User Generated Screeners


sarahgolliheroptions
pbarker46PEG
evseanLow Value Stock II
musselmantMODIFIED
sbeccuegf101-Industry
DANGORDONALL STOCKS 1-30-17
DANGORDONINFORMATION TECHNOLOGY 1-30-17
jpraschnikGreenblatt - Magic Formula
soho_analogBuy%20Back%20rate
pbarker46Shiller PE
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK